Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Carotid artery disease24.03.05.009; 17.08.02.0160.000154%Not Available
Spider vein24.10.04.003; 23.06.03.0060.000044%Not Available
Low turnover osteopathy20.01.01.010; 15.02.03.016; 14.04.04.0150.016541%Not Available
Spondylolisthesis15.10.04.004; 12.04.04.0080.000947%Not Available
Periodic limb movement disorder19.02.05.009; 17.15.04.006; 15.05.03.0340.000044%Not Available
Asthmatic crisis22.03.01.0180.000044%Not Available
Oroantral fistula22.04.06.005; 07.11.05.0150.000044%Not Available
Medial tibial stress syndrome15.02.04.0360.000044%Not Available
Oral cavity fistula07.11.05.0140.000352%
Stress urinary incontinence20.02.02.0220.000572%Not Available
Weight bearing difficulty15.03.05.034--Not Available
Retroperitoneal lymphadenopathy07.07.01.012; 01.09.01.0290.000044%Not Available
Carotid arteriosclerosis24.04.06.031; 17.08.02.0150.000066%Not Available
Fistula discharge15.03.02.015; 08.01.03.0690.000286%Not Available
Right atrial dilatation02.04.02.0320.000044%Not Available
Left atrial dilatation02.04.02.0250.000154%Not Available
Heart valve incompetence02.07.02.0030.000066%Not Available
Reflux laryngitis22.04.01.0070.000066%Not Available
Vertebral foraminal stenosis17.10.01.024; 15.01.08.0150.000418%Not Available
Limb asymmetry15.10.03.0090.000903%
Cerebral small vessel ischaemic disease24.04.06.034; 17.08.02.0200.000088%Not Available
Bone deformity15.10.03.0060.000066%Not Available
Exposed bone in jaw15.02.04.0340.000594%Not Available
Soft tissue mass15.03.02.0190.000088%Not Available
Spinal pain08.01.08.030; 17.10.01.020; 15.02.01.0080.000088%Not Available
Invasive ductal breast carcinoma21.05.01.021; 16.10.01.0130.000176%Not Available
Large intestine benign neoplasm16.05.01.004; 07.20.01.0130.000066%Not Available
Idiopathic orbital inflammation06.04.11.0020.000066%Not Available
Chronic papillomatous dermatitis23.01.04.005; 12.02.16.0020.000066%Not Available
Lumbosacral radiculopathy17.10.03.0050.000352%Not Available
The 36th Page    First    Pre   36 37 38 39    Next   Last    Total 39 Pages